|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UGT2B7 |
Gene summary for UGT2B7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UGT2B7 | Gene ID | 7364 |
| Gene name | UDP glucuronosyltransferase family 2 member B7 | |
| Gene Alias | UDPGT 2B7 | |
| Cytomap | 4q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006063 | UniProtAcc | P16662 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7364 | UGT2B7 | AEH-subject1 | Human | Endometrium | AEH | 7.33e-37 | 9.43e-01 | -0.3059 |
| 7364 | UGT2B7 | AEH-subject2 | Human | Endometrium | AEH | 4.38e-11 | 5.71e-01 | -0.2525 |
| 7364 | UGT2B7 | AEH-subject3 | Human | Endometrium | AEH | 1.56e-03 | 2.67e-01 | -0.2576 |
| 7364 | UGT2B7 | AEH-subject5 | Human | Endometrium | AEH | 4.10e-02 | 4.02e-01 | -0.2953 |
| 7364 | UGT2B7 | EEC-subject1 | Human | Endometrium | EEC | 5.99e-34 | 9.38e-01 | -0.2682 |
| 7364 | UGT2B7 | EEC-subject2 | Human | Endometrium | EEC | 1.42e-29 | 8.84e-01 | -0.2607 |
| 7364 | UGT2B7 | EEC-subject3 | Human | Endometrium | EEC | 1.87e-09 | 1.95e-01 | -0.2525 |
| 7364 | UGT2B7 | EEC-subject5 | Human | Endometrium | EEC | 1.46e-23 | 8.95e-01 | -0.249 |
| 7364 | UGT2B7 | GSM5276935 | Human | Endometrium | EEC | 1.04e-03 | -1.30e-01 | -0.123 |
| 7364 | UGT2B7 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 3.76e-07 | 9.96e-02 | -0.1869 |
| 7364 | UGT2B7 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 4.27e-07 | 2.80e-02 | -0.1875 |
| 7364 | UGT2B7 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 2.15e-09 | 1.82e-01 | -0.1883 |
| 7364 | UGT2B7 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 4.38e-06 | -7.80e-02 | -0.1934 |
| 7364 | UGT2B7 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 3.08e-23 | 4.35e-01 | -0.1917 |
| 7364 | UGT2B7 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 9.52e-15 | 3.57e-01 | -0.1916 |
| 7364 | UGT2B7 | NAFLD1 | Human | Liver | NAFLD | 2.89e-04 | 3.63e-01 | -0.04 |
| 7364 | UGT2B7 | HCC1_Meng | Human | Liver | HCC | 3.57e-68 | 1.24e-01 | 0.0246 |
| 7364 | UGT2B7 | HCC2 | Human | Liver | HCC | 6.48e-35 | 4.45e+00 | 0.5341 |
| 7364 | UGT2B7 | S027 | Human | Liver | HCC | 6.51e-20 | 1.43e+00 | 0.2446 |
| 7364 | UGT2B7 | S028 | Human | Liver | HCC | 1.35e-40 | 1.65e+00 | 0.2503 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00082023 | Liver | NAFLD | steroid metabolic process | 69/1882 | 319/18723 | 5.90e-10 | 1.28e-07 | 69 |
| GO:00424452 | Liver | NAFLD | hormone metabolic process | 36/1882 | 218/18723 | 1.98e-03 | 1.98e-02 | 36 |
| GO:0008210 | Liver | NAFLD | estrogen metabolic process | 10/1882 | 38/18723 | 3.49e-03 | 3.00e-02 | 10 |
| GO:00082022 | Liver | HCC | steroid metabolic process | 188/7958 | 319/18723 | 1.96e-09 | 5.63e-08 | 188 |
| GO:00082091 | Liver | HCC | androgen metabolic process | 21/7958 | 30/18723 | 2.15e-03 | 1.08e-02 | 21 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa012402 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
| hsa009832 | Liver | HCC | Drug metabolism - other enzymes | 54/4020 | 80/8465 | 2.25e-04 | 1.09e-03 | 6.08e-04 | 54 |
| hsa012403 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
| hsa009833 | Liver | HCC | Drug metabolism - other enzymes | 54/4020 | 80/8465 | 2.25e-04 | 1.09e-03 | 6.08e-04 | 54 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UGT2B7 | SNV | Missense_Mutation | rs138302870 | c.1201G>C | p.Asp401His | p.D401H | P16662 | protein_coding | deleterious(0.02) | benign(0.038) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
| UGT2B7 | SNV | Missense_Mutation | c.607N>A | p.Asp203Asn | p.D203N | P16662 | protein_coding | deleterious(0.02) | benign(0.386) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| UGT2B7 | SNV | Missense_Mutation | c.242T>C | p.Leu81Ser | p.L81S | P16662 | protein_coding | tolerated(0.21) | benign(0.077) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UGT2B7 | SNV | Missense_Mutation | novel | c.1562G>A | p.Arg521Lys | p.R521K | P16662 | protein_coding | tolerated(1) | benign(0.003) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| UGT2B7 | SNV | Missense_Mutation | c.472N>A | p.Glu158Lys | p.E158K | P16662 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| UGT2B7 | SNV | Missense_Mutation | novel | c.131N>G | p.Asp44Gly | p.D44G | P16662 | protein_coding | deleterious(0.05) | benign(0.419) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| UGT2B7 | SNV | Missense_Mutation | novel | c.1294N>T | p.Val432Leu | p.V432L | P16662 | protein_coding | deleterious(0.04) | benign(0.062) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| UGT2B7 | SNV | Missense_Mutation | c.851N>A | p.Pro284His | p.P284H | P16662 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UGT2B7 | SNV | Missense_Mutation | novel | c.1528N>C | p.Lys510Gln | p.K510Q | P16662 | protein_coding | deleterious(0.04) | probably_damaging(0.969) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| UGT2B7 | SNV | Missense_Mutation | c.1004T>G | p.Val335Gly | p.V335G | P16662 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7364 | UGT2B7 | DRUGGABLE GENOME | methadone | METHADONE | 17178267,22676193 | |
| 7364 | UGT2B7 | DRUGGABLE GENOME | codeine | CODEINE | 25752520 | |
| 7364 | UGT2B7 | DRUGGABLE GENOME | lamotrigine | LAMOTRIGINE | 26213157,26790665,27096250,23263737 | |
| 7364 | UGT2B7 | DRUGGABLE GENOME | oxycodone | OXYCODONE | 29502154 | |
| 7364 | UGT2B7 | DRUGGABLE GENOME | buprenorphine | BUPRENORPHINE | 24256307 | |
| 7364 | UGT2B7 | DRUGGABLE GENOME | fluvastatin | FLUVASTATIN | ||
| 7364 | UGT2B7 | DRUGGABLE GENOME | simvastatin | SIMVASTATIN | ||
| 7364 | UGT2B7 | DRUGGABLE GENOME | morphine | MORPHINE | 17724700,25340733,24703092,16580900,12185559,28063968,31607718 | |
| 7364 | UGT2B7 | DRUGGABLE GENOME | aprepitant | APREPITANT | 26053558 | |
| 7364 | UGT2B7 | DRUGGABLE GENOME | fentanyl | FENTANYL | 32401749 |
| Page: 1 2 3 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |